Together, we can identify patients at risk and save lives

Extensive clinical evidence supports the WCD as a therapy for protection from SCD.
Share the video with your practice to educate them about SCD risk and prevention.
View stories from patients who have benefited from the LifeVest WCD.
MEET a Lifevest Patient


1. Halkin A et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: CADILLAC risk score. J Am Coll Cardiol 2005;45:1397–1405.

2. Solomon SD et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. NEJM 2005;352:2581–2588.

3. Adabag AS et al. Sudden death after myocardial infarction. JAMA 2008;300(17):2022–2029.

4. Kutyifa V et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: Data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II Registry). Circulation 2015;132(17):1613–1619.

5. Kutyifa V et al. One-year follow-up of the prospective registry of patients using the wearable defibrillator (WEARIT-II Registry). Presented as late breaking clinical trial at the 2016 CARDIOSTIM EHRA EUROPACE Congress, June 10, 2016.

6. Al-Khatib SM et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. J Am Coll Cardiol 2017, doi: 10.1016/j.jack.2017.10.054.